title: The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation.
abstract: Prostate cancer is the most commonly diagnosed cancer, with an estimated 240,000 new cases reported annually in the United States. Due to early detection and advances in therapies, more than 90% of patients will survive 10 years post diagnosis and treatment. Radiation is a treatment option often used to treat localized disease; however, while radiation is very effective at killing tumor cells, normal tissues are damaged as well. Potential side-effects due to prostate cancer-related radiation therapy include bowel inflammation, erectile dysfunction, urethral stricture, rectal bleeding and incontinence. Currently, radiation therapy for prostate cancer does not include the administration of therapeutic agents to reduce these side effects and protect normal tissues from radiation-induced damage. In the current study, we show that the small molecular weight antioxidant, MnTE-2-PyP, protects normal tissues from radiation-induced damage in the lower abdomen in rats. Specifically, MnTE-2-PyP protected skin, prostate, and testes from radiation-induced damage. MnTE-2-PyP also protected from erectile dysfunction, a persistent problem regardless of the type of radiation techniques used because the penile neurovascular bundles lay in the peripheral zones of the prostate, where most prostate cancers reside. Based on previous studies showing that MnTE-2-PyP, in combination with radiation, further reduces subcutaneous tumor growth, we believe that MnTE-2-PyP represents an excellent radioprotectant in combination radiotherapy for cancer in general and specifically for prostate cancer.
authors.affiliation: Pulmonary Division, Department of Medicine, National Jewish Health, Denver, Colorado, United States of America.
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Oberley-Deegan
authors.forename: Joshua J
authors.initials: JJ
authors.lastname: Steffan
authors.forename: Kyle O
authors.initials: KO
authors.lastname: Rove
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Pate
authors.forename: Michael W
authors.initials: MW
authors.lastname: Weaver
authors.forename: Ivan
authors.initials: I
authors.lastname: Spasojevic
authors.forename: Barbara
authors.initials: B
authors.lastname: Frederick
authors.forename: David
authors.initials: D
authors.lastname: Raben
authors.forename: Randall B
authors.initials: RB
authors.lastname: Meacham
authors.forename: James D
authors.initials: JD
authors.lastname: Crapo
authors.forename: Hari K
authors.initials: HK
authors.lastname: Koul
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000493:pharmacokinetics / Q000494:pharmacology*; D004249:DNA Damage; D007172:Erectile Dysfunction / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008665:Metalloporphyrins / Q000493:pharmacokinetics / Q000494:pharmacology*; D008954:Models, Biological; D010413:Penis / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000503:physiopathology / Q000532:radiotherapy*; D011839:Radiation, Ionizing; D011837:Radiation-Protective Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D011878:Radiotherapy / Q000009:adverse effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology / Q000528:radiation effects; D013737:Testis / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology / Q000528:radiation effects
chemical_list: D000975:Antioxidants; D008665:Metalloporphyrins; D011837:Radiation-Protective Agents; C520506:manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin